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Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver 
that actively contribute to liver damage. Sirtuin 1 (SIRT1) regulates liver regeneration and bile acid metabolism by 
modulating farnesoid X receptor (FXR); we here investigate its role in cholestatic liver disease. We determined 
SIRT1 expression in livers from patients with cholestatic disease, in two experimental models of cholestasis, as well 
as in human and murine liver cells in response to bile acid loading. SIRT1-overexpressing (SIRToe) and hepatocyte-
specific SIRT1-KO (knockout) mice (SIRThep–/–) were subjected to bile duct ligation (BDL) and were fed with a 
0.1% DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine) diet to determine the biological relevance of SIRT1 during 
cholestasis. The effect of NorUDCA (24-norursodeoxycholic acid) was tested in BDL/SIRToe mice. We found that 
SIRT1 was highly expressed in livers from cholestatic patients, mice after BDL, and Mdr2 knockout mice (Mdr2–/–) 
animals. The detrimental effects of SIRT1 during cholestasis were validated in vivo and in vitro. SIRToe mice 
showed exacerbated parenchymal injury whereas SIRThep–/– mice evidenced a moderate improvement after BDL and 
0.1% DDC feeding. Likewise, hepatocytes isolated from SIRToe mice showed increased apoptosis in response to bile 
acids, whereas a significant reduction was observed in SIRThep–/– hepatocytes. Importantly, the decrease, but not 
complete inhibition, of SIRT1 exerted by norUDCA treatment correlated with pronounced improvement in liver 
parenchyma in BDL/SIRToe mice. Interestingly, both SIRT1 overexpression and hepatocyte-specific SIRT1 deple-
tion correlated with inhibition of FXR, whereas modulation of SIRT1 by NorUDCA associated with restored FXR 
signaling. Conclusion: SIRT1 expression is increased during human and murine cholestasis. Fine-tuning expression 
of SIRT1 is essential to protect the liver from cholestatic liver damage. (Hepatology 2019;69:699-716).
The term cholestatic liver disease (CLD) includes a broad spectrum of aetiologically heterogeneous hepatobiliary disorders, mainly 
comprising primary biliary cholangitis (PBC) and 
primary sclerosing cholangitis (PSC), in adults. These 
conditions are characterized by accumulation of bile 
acids in the liver, leading to hepatocellular necrosis 
and apoptosis, progressive fibrosis, and end-stage liver 
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disease.(1-3) Current therapeutic approaches for treat-
ing cholestasis mainly rely on the use of ursodeoxy-
cholic acid (UDCA); however, this treatment has no 
proven efficacy for PSC and a proportion of patients 
with PBC.(2,3) The therapeutic options for such unre-
sponsive patients are currently limited, though there 
have been recent promising advances, including the 
use of 24-norursodeoxycholic acid (NorUDCA),(4) 
which has been shown to improve liver function in 
PSC patients in a recent clinical trial.(5) Also, novel 
treatments using fibrates(6) and farnesoid X receptor 
(FXR) agonists, such as obeticholic acid,(7-9) have 
shown efficacy for PBC patients unresponsive to 
UDCA. Still, a better understanding of the molec-
ular mechanism underpinning the pathogenesis of 
cholestasis will enable the development of efficient 
therapies for cholestatic patients.
FXR is an orphan nuclear receptor that plays a key 
role in the regulation of bile acid metabolism and in 
the pathogenesis of cholestasis.(6,10-13) Regulation of 
FXR involves a dynamic acetylation/deacetylation 
process mediated by p300 and Sirtuin 1 (SIRT1), 
respectively.(14) SIRT1 deacetylates FXR, increasing 
its DNA binding and dependent gene transcription. 
Interestingly, SIRT1/FXR interaction must be finely 
tuned, given that prolonged SIRT1-mediated FXR 
deacetylation leads to ubiquitination and proteasome 
degradation.(14)
SIRT1 is an evolutionarily conserved nicotinamide 
adenine dinucleotide+–dependent histone III deacety-
lase that is activated in response to energy depriva-
tion, controlling key metabolic functions, including 
bile acid metabolism.(15,16) Initial work delineating 
the implication of SIRT1 in prolonging the life span 
in lower organisms(17) and in promoting healthy aging 
in mammals(18) led to SIRT1 being hyped as a “magic 
bullet” to preserve lifelong health. Nevertheless, the 
role of SIRT1 has been revealed to be highly complex 
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in a wide range of biological functions, including tum-
origenesis. We and others have described SIRT1 as 
being highly expressed in human liver tumors,(16,19,20) 
pointing to the potential contribution of SIRT1 to 
liver disease. Supporting this, we demonstrated that 
SIRT1 overexpression leads to impaired liver regen-
eration after partial hepatectomy, which associated 
with disturbances in bile acid homeostasis, including 
reduced FXR signaling, increased synthesis and accu-
mulation of toxic bile acids in the liver.(16) Overall, 
these results led us to hypothesise that SIRT1 may 
play a role during CLD.
In accord, in this study, we suggest that SIRT1 is 
up-regulated in the liver during human cholestasis in 
PSC and PBC patients and in two murine models of 
cholestasis; after bile duct ligation (BDL) and in Mdr2 
knockout mice (Mdr2–/–) mice. We further demon-
strate that SIRT1 contributes to liver parenchymal 
damage in the context of obstructive cholestasis, given 
that overexpression of SIRT1 aggravates liver injury, 
whereas hepatocyte-specific SIRT1 depletion exerts a 
moderate cell protection after BDL and feeding with 
a diet containing 0.1% of DDC (3,5-diethoxycarbon-
yl-1,4-dihydrocollidine). Importantly, the improve-
ment in liver function observed in hepatocyte-specific 
SIRT1 KO (knockout) mice is only transient, likely 
involving mechanisms including the attenuation of 
FXR signaling. Ultimately, we describe that the ben-
eficial effect of NorUDCA treatment in reducing 
liver injury in cholestatic SIRT1-overexpressing mice 
associates with the modulation, though not complete 
depletion, of SIRT1 expression.
Overall, our results support the importance of 
maintaining SIRT1 fine-tuned expression to preserve 
liver function in the context of cholestatic disease.
Materials and Methods
HUMaN pBC aND pSC SaMpleS
SIRT1 gene expression was determined by qPCR 
analysis in mRNA isolated from cirrhotic livers of 
patients with PBC (n = 10) and PSC (n = 10) who 
underwent liver transplantation. Control liver tis-
sues (n = 5) were acquired from large-margin liver 
resections from patients undergoing of colorectal 
metastases with no microscopic changes of liver 
disease identified by a pathologist, all collected in 
the Department of General, Transplant and Liver 
Surgery, Medical University of Warsaw (Warsaw, 
Poland), as described elsewhere.(21) Supporting 
Table S1 includes detailed clinical and biochemical 
data of these patients.
Protein expression of SIRT1 was assessed by immu-
nohistochemistry (IHC) in paraffin-embedded sections 
from livers obtained by percutaneous biopsy from n = 9 
PBC patients, n = 5 PSC patients, and in liver samples 
obtained from n = 4 healthy individuals at the Norwich 
Norfolk University Hospital (Norwich, UK). The diag-
nosis was established by pathological analysis of liver 
biopsies together with presence of antimitochondrial 
antibodies in the case of PBC. Clinical and biochem-
ical data of these patients are included in Supporting 
Table S2. Use of human tissue samples was approved by 
the Faculty of Medicine and Health Sciences Research 
Ethics committee (University of East Anglia, Norwich, 
UK). Collection and handling of human samples used 
in this study conformed to the Declaration of Helsinki 
and the Human Tissue Act (UK) and Good Clinical 
Practice Guidelines (UK).
eXperIMeNtal proCeDUreS IN 
aNIMalS
All experimental procedures were conducted in male 
mice from 8-12 weeks of age and were performed at 
the CICbioGUNE animal facility and at the Disease 
Modelling Unit (University of East Anglia, UK) 
and were previously approved by the Department of 
Environment, Planning, Agriculture and Fisheries 
(Basque Country Government, Spain) and by the Animal 
Welfare and Ethical Review Body (AWERB, University 
of East Anglia, Norwich, UK) respectively. All experi-
ments were performed following the guidelines of the 
National Academy of Sciences (National Institutes of 
Health publication 86-23, revised 1985) and were con-
ducted within the provisions of the Animals (Scientific 
Procedures) Act 1986 (ASPA) and the LASA Guiding 
Principles for Preparing for and Undertaking Aseptic 
Surgery (2010) under UK Home Office approval.
More information is available in the Supporting 
Materials and Methods.
StatIStICal aNalySIS
Data are expressed as mean ± standard error of 
the mean. Statistical significance was determined by 
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two-way analysis of variance (ANOVA) followed by a 
Student’s t test or by a Student’s t test only as appro-
priate using Graph Pad Prism software.
Results
SIrt1 IS Up-regUlateD 
DUrINg HUMaN aND MUrINe 
CHoleStaSIS
Expression of SIRT1 during PBC and PSC, the 
main human CLD etiologies, has not been character-
ized to date. SIRT1 was highly expressed in choles-
tatic livers from PBC and PSC patients at the gene 
transcript level (Fig. 1A). IHC analysis evidenced 
increased positive SIRT1 immunostaining mainly 
localized in the nuclei of hepatocytes and bile duct 
cells in PBC and PSC patients (Fig. 1B,C). In con-
trast, lower and more-diffuse SIRT1 staining was 
detected in livers from healthy individuals (Fig. 1B,C). 
These results suggest that increased SIRT1 nuclear 
expression relates to the cholestasis itself and not to 
the specific etiology of the disease.
To determine whether bile acids have a direct effect 
on triggering SIRT1 up-regulation during cholesta-
sis, we exposed THLE-2 cells (liver epithelial cells of 
human origin) to different bile acids, including pri-
mary and secondary species, and found a significant 
increase in SIRT1 expression (Fig. 1D).
FIg. 1. SIRT1 is highly expressed in livers from cholestatic PBC and PSC patients and is induced in response to bile acids in vitro. (A) 
qPCR analysis of SIRT1 expression in liver samples from healthy individuals (n = 5), PBC (n = 10), and PSC (n = 10) and (B) IHC using 
an anti-SIRT1 Ab in liver sections from cholestatic patients compared to healthy donors showing increased gene and protein expression 
and protein nuclear localization of SIRT1 in hepatocytes and cholangiocytes during cholestasis (original magnification, ×10) with (C) 
quantification of positively stained nuclei. Healthy individuals, n = 4; PBC, n = 9; PSC, n = 5. (D) qPCR analysis of SIRT1 expression 
in THLE2 cells cultured for 3 hours with CA, GCA, CDCA, and DCA and at the doses indicated. Values are mean ± SEM; in vitro 
experiments were performed three times in triplicate; *P < 0.05; **P < 0.01. Abbreviation: Ab, antibody.
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Further studies in murine models of cholestasis 
confirmed that SIRT1 is up-regulated at different 
time points after BDL at gene (Fig. 2A) and protein 
level (Fig. 2B-D and Supporting Fig. S1A) in wild-
type (WT) mice (Fig. 2C,D). No changes in SIRT1 
expression were observed in livers from sham-oper-
ated mice (Supporting Fig. S1B,C).
In accord with our results in mice after BDL, 
analysis of liver tissue samples from Mdr2–/– mice, 
a well-established mouse model resembling PSC,(22) 
FIg. 2. SIRT1 expression is up-regulated during surgically and genetically induced murine cholestasis. (A) qPCR analysis of SIRT1 
expression in livers from WT mice at different time points after BDL showing up-regulation during cholestasis. (B) Western blotting 
analysis on liver nuclear extracts from WT mice and (C) IHC on liver sections and (D) further quantification of SIRT1-positive nuclei 
after BDL, indicating increased SIRT1 expression and nuclear localization during cholestasis. (E) IHC in liver sections of WT and 
Mdr2–/– mice and (F) quantification of SIRT1-positive nuclei. Values are mean ± SEM; n ≥ 5 animals/time point; **P < 0.01.
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showed an increased number of hepatocytes express-
ing SIRT1, as evidenced by IHC and further quan-
tification of positive hepatocytes (Fig. 2F), and 
higher protein expression in nuclear liver extracts, 
as shown by immunoblotting analysis (Supporting 
Fig. S1D,E).
In vitro studies in primary hepatocytes from WT 
mice supported our observations in human liver cells 
(Fig. 1D), showing SIRT1 up-regulation in response 
to chenodeoxycholic acid (CDCA), deoxycholic acid 
(DCA), glycocholic acid (GCA), and cholic acid 
(CA) at a dose of 125 µM (Supporting Fig. S2A). 
Increased SIRT1 expression in hepatocytes associ-
ated with augmented apoptosis after bile acid load 
(Supporting Fig. S2B) was not altered in the pres-
ence of caspase-3 inhibitor (Supporting Fig. S2C), 
supporting that SIRT1 up-regulation is not result-
ing from increased apoptosis. Further studies using 
the bile acid species with a higher impact on cell 
death showed that CDCA and DCA triggered 5’ 
adenosine monophosphate-activated protein kinase 
(AMPK) phosphorylation (Supporting Fig. S2D). 
Inhibition of AMPK activity partially reduced 
SIRT1 expression (Supporting Fig. S2E) and 
decreased apoptosis (Supporting Fig. S2F). SIRT1 
and AMPK are key metabolic regulators activated 
in response to changes in nutrient or energy avail-
ability.(23,24) Importantly, serum supplementation to 
the culture media reduced AMPK phosphorylation 
(Supporting Fig. S2G), SIRT1 expression (although 
still present; Supporting Fig. S2H), and apoptosis 
(Supporting Fig. S2I) in response to bile acids.
Overall, our results indicate that SIRT1 expression 
increases during cholestasis, likely driven by accumu-
lation of bile acids, contributing to hepatocyte cell 
death.
SIrt1 oVereXpreSSIoN 
aggraVateS lIVer INJUry, 
INFlaMMatIoN, aND 
FIBrogeNeSIS aFter BDl
To gain further insight into the biological rele-
vance of increased SIRT1 expression during CLD, 
we performed BDL in mice that overexpress SIRT1 
(Supporting Fig. S3A,B; hereafter, SIRToe mice).
The increase in serum markers of liver function 
and the profuse presence of necrotic areas observed 
in SIRToe mice evidenced the detrimental impact of 
SIRT1 overexpression during cholestasis (Fig. 3A,B). 
Analysis of caspase-3 activity (Supporting Fig. S3C) 
and terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) assay (Fig. 3C and Supporting 
Fig. S3D) supported that higher apoptotic cell death 
occurs after BDL in SIRToe mice compared to WT 
animals.
In vitro analyses in isolated hepatocytes from 
SIRToe mice confirmed that overexpression of SIRT1 
further sensitizes liver cells to bile-acid–induced apop-
totic cell death (Fig. 3D and Supporting Fig. S3E).
Characterization of inflammatory response by flu-
orescent-activated cell sorting (FACS) analysis of liv-
er-isolated immune cells showed that SIRToe mice had 
higher presence of macrophages at 7 days after BDL 
compared to WT mice (Fig. 3E). Analysis of cyto-
kine (interleukin [IL]1β, IL6, and interferon-gamma 
[IFNγ]), activation factors (nitric oxide synthase 2; 
NOS2), chemokine (C-C motif chemokine ligand 2; 
CCL2), and chemokine receptor (CC-type chemok-
ine receptor [CCR]1, CCR2, and CCR5) expression 
confirmed the increased proinflammatory milieu in 
SIRToe mice compared to WT after BDL. Tumor 
necrosis factor alpha (TNFα) expression was com-
parable in both genotypes (Fig. 3F). TNFα, IL6, and 
CCL2 enzyme-linked immunosorbent assay (ELISA) 
confirmed the gene expression results obtained 
(Supporting Fig. S3F).
Finally, fibrogenesis was assessed in SIRToe and 
WT mice after BDL. Sirius Red staining (Fig. 3G 
and Supporting Fig. S3G, left panels), alpha-smooth 
muscle actin (αSMA) determination by IHC on liver 
sections (Fig. 3G and Supporting Fig. S3G, right pan-
els), followed by quantification (Fig. 3G) and qPCR 
analysis of collagen 1A1, αSMA, and transforming 
growth factor beta gene expression (Supporting Fig. 
S3H) supported increased fibrogenesis in SIRToe ani-
mals compared to WT mice after BDL.
Analysis of WT and SIRToe mice at 3 and 7 
days after sham surgery showed no significant dif-
ferences compared to control animals in the param-
eters described above, including serum liver damage 
markers (Supporting Fig. S4A), liver parenchyma 
status (Supporting Fig. S4B), hepatocyte apoptosis 
(Supporting Fig. S4C), inflammation (Supporting 
Fig. S4D,E), and fibrosis (Supporting Fig. S4F,G). 
Macrophage counts and caspase-3 were slightly 
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increased in sham WT and SIRToe mice, respec-
tively, compared to control mice, though these param-
eters were still significantly different in BDL mice, 
supporting the specificity of the biological response 
observed after BDL.
Overall, our results suggest that SIRT1 overex-
pression aggravates liver injury, hepatocellular death, 
inflammation, and consequent fibrogenesis in the 
context of cholestasis.
SIrt1 oVereXpreSSIoN alterS 
FXr-MeDIateD regUlatIoN oF 
BIle aCID SyNtHeSIS
During cholestasis, FXR mediates compensatory 
responses aiming at inhibiting endogenous bile acid 
production and regulating their transport, in a coordi-
nated manner with other nuclear receptors.(12)
In line with the described cross-talk regula-
tion,(12-14) we found that SIRT1 overexpression asso-
ciates with decreased FXR protein expression during 
cholestasis. Whereas WT mice showed a transient 
increase in FXR at 3 days after BDL that ameliorated 
after 7 days, SIRToe mice had persistently lower FXR 
levels (Fig. 4A). Lower small heterodimer partner 
(SHP) and higher cholesterol 7 hydroxylase (Cyp7A1) 
expression found in SIRToe mice compared to WTs at 
3 days after BDL confirmed the impaired FXR sig-
naling in the context of SIRT1 overexpression at this 
time point (Fig. 4B).
Further analysis of liver bile acid content showed 
an enlarged pool size in SIRToe mice after BDL 
FIg. 3. Overexpression of SIRT1 leads to increased parenchymal injury and fibrogenesis in mice after BDL. (A) Profiles of blood liver 
injury markers detected in WT and SIRToe animals and (B) H&E staining of liver sections from WT and SIRToe animals after BDL 
showing profuse liver damage in SIRToe mice. (C) TUNEL assay on liver sections showing increased presence of apoptotic hepatocytes 
in SIRToe mice compared to WT after BDL. (D) Caspase-3 activity was determined in primary hepatocytes isolated from WT and 
SIRToe mice and cultured in the presence of CDCA and DCA. (E) FACS analysis on liver isolated immune cells and (F) qPCR 
analyses of inf lammation markers showed increased presence of macrophages and increased proinflammatory response in SIRToe mice. 
(G) Liver fibrogenesis was characterized by Sirius Red staining on liver sections (left panels) and SMA IHC (right panels) from mice 
after BDL, followed by morphometric quantification using Frida software expressed in % of positive staining per power field (ppf). 
Images are representative of n ≥ 5 animals/time point; values are mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0 .001 (WT vs. SIRToe). 
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase.
FIg. 4. Overexpression of SIRT1 correlates with lower presence and activity of FXR and higher accumulation of bile acids in liver. (A) 
Western blotting of whole-protein extracts using FXR Ab and further quantification using Image Lab software (Bio-Rad, Hercules, 
CA) showing reduced protein presence in SIRToe mice. (B) Gene expression analysis of SHP and Cyp7a1 by qPCR in livers 3 and 7 days 
after BDL. (C) Quantification of bile acid pool size in livers from WT and SIRT mice after BDL by HPLC. (D) qPCR analysis of bile 
acid transporters after BDL. Values are mean ± SEM; n ≥ 5 animals/time point; *P < 0.05; **P < 0.01 (WT vs. SIRToe). Abbreviations: 
Ab, antibody; HPLC, high-performance liquid chromatography.
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compared to WT animals (Fig. 4C) whereas no sig-
nificant differences were detected in fecal excretion 
(Supporting Fig. S5A). Analysis of bile acid trans-
porters showed no significant differences between 
WT and SIRToe mice in organic anion transporting 
polypeptide (Oatp), sodium taurocholate cotransport-
ing polypeptide (Ntcp), bile salt export pump (Bsep), 
or multidrug resistance-associated protein 4 (Mrp4) 
expression (Fig. 4D), supporting that increased bile 
acid accumulation in SIRToe mice resulted from 
higher synthesis.
Sham surgery had no impact on modulating FXR 
signaling or bile acid transporter expression compared 
to untreated control mice, with the exception of Ntcp, 
FIg. 5. SIRT1 overexpression correlates with attenuation of cholangiocyte proliferation. (A) IHC using an anti-CK19 Ab in paraffin-
embedded liver sections at different time points after BDL and (B) further quantification using Frida software, expressed in % of positive 
staining ppf (original magnification, ×10) showing milder ductular reaction in SIRT mice compared to WTs. (C) Determination of 
caspase-3 activity in response to CDCA on NMCs transfected with control c-Flag pcDNA3 (Ctrl) or pCruzHA SIRT1 plasmid DNA 
to induce overexpression of SIRT1 (SIRToe). (D) qPCR analysis of cell-cycle–related gene expression in Ctrl and SIRToe transfected 
NMC showing lower proliferation in the presence of growth factors (EGF) 36 hours after transfection. (E) FACS analysis of PI-
stained NMCs confirming lower numbers of cells in S phase after SIRT1 overexpression compared to control transfected cells. (F) 
Representative histograms after FACS analysis of NMC transfected cells in culture. Values are mean ± SD; n = 5 animals/time point; 
in vitro experiments were performed three times in triplicate; *P < 0.05; **P < 0.01 (WT vs. SIRT); (Ctrl vs. SIRT1oe). Abbreviations: 
Ab, antibody; EGF, epidermal growth factor; PI, propidium iodide; ppf, per power field; ShCtrl, short hairpin control.
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of which expression was reduced in sham mice com-
pared to control animals, but was still significantly 
different from WT/BDL and SIRToe/BDL mice 
(Supporting Fig. S5B-D).
Overall, our results demonstrate that SIRT1 over-
expression contributes to the accumulation of bile 
acids in the liver during cholestasis upon attenuation 
of FXR-mediated inhibition of bile acid synthesis.
SIrt1 oVereXpreSSIoN 
atteNUateS CHolaNgIoCyte 
prolIFeratIoN
Liver cholestasis is characterized by chronic 
bile duct injury with proliferation of cholangio-
cytes (ductular reaction) at the early stages and later 
ductopenia.(1,3)
Interestingly, cytokeratin 19 (CK19) immunos-
taining on liver sections showed a moderate increase 
of the ductular reaction in WT compared to SIRToe 
mice (Fig. 5A,B).
Aiming to determine how SIRT1 may influence 
cholangiocyte function, we performed in vitro anal-
ysis of normal mouse cholangiocytes (NMCs), where 
we induced overexpression of SIRT1 by transfecting 
with a plasmid DNA (SIRT1oe). An empty vector 
was transfected as control (Control). We found that 
SIRT1oe/NMC showed similar apoptotic response 
to bile acid stimulation when compared to control/
NMC (Fig. 5C). Further analysis of cell-cycle regu-
lation revealed that SIRT1oe NMC had lower cyclin 
D1 and E expression when cultured in the presence 
of growth factors, suggesting that SIRT1 overex-
pression may attenuate cell proliferation (Fig 5D). 
Finally, FACS analysis, showing a higher percentage 
of SIRT1oe/NMC arrested in the G1 phase compared 
to control cells (Fig. 5E,F), confirmed that SIRT1 
overexpression attenuates cholangiocyte proliferation.
SIrt1 oVereXpreSSIoN 
CoNtrIBUteS to INCreaSeD 
lIVer INJUry aND 
FIBrogeNeSIS aFter 0.1%  
DDC–INDUCeD CHoleStaSIS
The detrimental impact of SIRT1 overexpression 
during cholestasis was further confirmed in an addi-
tional experimental model where 0.1% DDC–fed 
SIRToe mice showed increased alkaline phospha-
tase (AP) serum levels (Supporting Fig. S6A) and 
wider areas of liver necrosis after 1 week of treatment 
(Supporting Fig. S6B). Though not prominent, 0.1% 
DDC/SIRToe showed increased cell death (Supporting 
Fig. S6C,D) compared to 0.1% DDC/WT animals. 
As observed after BDL, SIRToe mice showed milder 
ductular reaction, as evidenced by CK19 immunos-
taining (Supporting Fig. S6E) and higher fibrosis 
(Supporting Fig. S6F) than WT animals after DDC. 
Western blotting analysis showed strong reduction 
of FXR in both genotypes after DDC diet, although 
expression was found to be lower in SIRToe mice 
compared to WT animals (Supporting Fig. S6G).
Overall, our results in this alternative model of 
cholestasis support the detrimental impact that SIRT1 
overexpression has on liver damage during cholestasis.
HepatoCyte-SpeCIFIC SIrt1 
DepletIoN leaDS to a 
MoDerate, BUt traNSIeNt, 
atteNUatIoN oF CHoleStatIC 
lIVer INJUry aFter BDl
Our results indicate that SIRT1 overexpression 
contributes to aggravation of liver damage during 
cholestasis, pointing to modulation of SIRT1 as a 
therapeutic approach. Next, we aimed to investigate 
how hepatocyte-specific SIRT1 depletion may impact 
on liver injury during BDL-induced cholestasis.
We found that hepatocyte-specific SIRT1 KO 
mice (SIRThep–/–) with only residual SIRT1 expres-
sion in the liver (Supporting Fig. S7A,B) showed a 
moderate improvement on liver damage markers and 
liver parenchymal status (Fig. 6A,B), whereas liver 
injury seemed to reach comparable levels as WT mice 
at later time points (7 days) after BDL (Fig. 6A,B). 
Quantification of apoptotic response by TUNEL assay 
(Fig. 6C and Supporting Fig. S7C) and caspase-3 
activity (Supporting Fig. S7D) showed a reduction of 
apoptotic cell death in SIRThep–/– mice compared to 
WT mice after BDL.
In vitro analysis confirmed that hepatocytes iso-
lated from SIRThep–/– mice had a significantly lower 
apoptotic response to DCA and CDCA (Fig. 6D), 
whereas overall cell survival was lower in KO cells 
when compared to WT cells (Supporting Fig. S7E), 
indicating an increase in necrosis. Interestingly, 
Hepatology, Vol. 69, No. 2, 2019 Blokker et al.
709
Blokker et al. Hepatology, February 2019
710
hepatocytes isolated from SIRThep–/– mice showed 
reduced phosphorylated AMPK levels (Supporting 
Fig. S7F) after bile acid stimulation, supporting the 
cross-talk between SIRT1 and AMPK in response 
to bile acids. In line with the reduction in apop-
tosis upon SIRT1 depletion, inhibition of AMPK 
blunted bile-acid–induced apoptosis (Supporting 
Fig. S7G).
Liver inflammation was comparable in SIRThep–/– 
mice and WT animals after BDL given that there 
were no significant differences in liver macrophages 
(Fig. 6E) or in expression TNF, IFNγ, IL10, NOS2, 
CCL2, CCR2, and CCR5 (Fig. 6F and Supporting 
Fig. S8A). The mild increase in IL6, IL1β, and CCR1 
in SIRThep–/– mice was not statistically significant. We 
found no significant differences in ductular reaction 
(Supporting Fig. S8B,C) or degree of fibrosis (Fig. 6G 
and Supporting Fig. S8D,E) in SIRThep–/– mice com-
pared to WT animals after BDL.
Interestingly, SIRThep–/– mice had lower FXR pro-
tein expression 3 and 7 days after BDL compared 
to WT littermates (Fig. 7A). Reduced FXR cor-
related with lower SHP and higher Cyp7A1 expres-
sion in SIRThep–/– mice at 3 days after BDL that 
were further regulated 7 days after surgery similarly 
in both WT and KO mice (Fig. 7B). Accordingly, 
FIg. 6. Hepatocyte-specific SIRT1 depletion has a transient effect on protecting the liver from cholestatic injury by modulating 
apoptotic cell death whereas it has no impact on liver inf lammation, ductular reaction, and fibrosis. (A) Levels of serum liver damage 
markers of WT and SIRThep–/– animals and (B) H&E staining of liver sections from WT and SIRThep–/– animals after BDL showing 
transient improvement of the damaging liver phenotype in SIRThep–/– mice compared to WT. (C) TUNEL assay on liver sections 
showing decreased presence of apoptotic hepatocytes in SIRThep–/– mice compared to WT after BDL. (D) Quantification of caspase-3 
activity and in CDCA- and DCA-treated primary hepatocytes isolated from WT and SIRThep–/– mice showing a decrease apoptosis 
in SIRThep–/– mice, indicating an increase in necrosis. (E) FACS analysis on liver isolated immune cells and (F) ELISA on liver 
extracts showed comparable presence of macrophages and cytokine production in SIRThep–/– and WT mice. (G) Liver fibrogenesis was 
characterized by Sirius Red staining on liver sections (left panels) and aSMA IHC (right panels) from mice after BDL followed by 
quantification using Frida software expressed in % of positive staining per power field (ppf). All images at original magnification 10×. 
Values are mean ± SEM; n ≥ 5 animals/time point; in vitro experiments were performed three times in triplicate; *P < 0.05; **P < 0.01 
(WT vs. SIRThep–/–).
FIg. 7. Hepatocyte-specific SIRT1 depletion associates with reduced FXR expression and signaling after BDL and comparable bile 
acid transporters expression than WT littermates. (A) Western blotting of whole-protein extracts and further quantification using 
ImageLab software (Bio-Rad, Hercules, CA) showing reduced FXR in SIRThep–/– mice after BDL. (B) Gene expression analysis of 
SHP and Cyp7a1 and (C) bile acid transporters by qPCR in livers 3 and 7 days after BDL. (D) Quantification of bile acid pool size 
in livers from WT and SIRThep–/– mice after BDL by MS-HPLC. Values are mean ± SEM; n ≥ 5 animals/time point; **P < 0.01 WT 
versus SIRThep–/–). Abbreviations: HPLC, high-performance liquid chromatography; MS, mass spectrometry.
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with the increased SIRT1, we found reduced FXR 
acetylation at 3 and 7 days after BDL in WT mice 
(Supporting Fig. S9A). In accord with our observa-
tions, FXR acetylation and total protein expression 
were further reduced in SIRThep–/– mice (Supporting 
Fig. S9A). Consequently, an increased accumulation 
of bile acids in liver of SIRThep–/– mice was observed 
after BDL (Fig. 7C), though this did not reach sta-
tistical significance. Expression of bile acid trans-
porters was comparable between SIRThep–/– and WT 
mice after BDL (Fig. 7D), supporting that increased 
BA synthesis is a consequence of attenuated FXR 
signaling in the absence of hepatocytic SIRT1 and 
not to changes in transport. Though not statistically 
significant, Mrp4 expression was slightly higher in 
SIRThep–/– mice compared to WT animals, which 
could reflect a slight increase in alternative trans-
port of bile acids, overall impacting on total bile 
acid pool size.
Sham surgery had no impact on modulating 
liver injury (Supporting Fig. S10A-C), inflamma-
tion (Supporting Fig. S10D,E), ductular reaction 
(Supporting Fig. S10F), and fibrosis (Supporting Fig. 
S10G,H) in SIRThep–/– mice.
Overall, our results suggest that SIRT1-hepatocyte 
depletion exerts a degree of protection against bile-
acid–induced apoptosis, but not necrosis, explaining 
the transient benefits observed during cholestasis in 
vivo in SIRThep–/– mice.
HepatoCyte-SpeCIFIC SIrt1 
DepletIoN leaDS to a 
MoDerate, BUt traNSIeNt, 
atteNUatIoN oF CHoleStatIC 
lIVer INJUry aFter 0.1% DDC 
DIet FeeDINg
Further analyses in 0.1% DDC–treated SIRThep–/– 
mice confirmed our results obtained in the BDL 
experimental model, given that, despite the reduc-
tion in levels of liver damage serum markers in 
SIRThep–/– mice compared to WTs (Supporting Fig. 
S11A), no significant differences in parenchyma 
structure were detected (Supporting Fig. S11B). 
Similarly to what was found after BDL, though not 
prominent, 0.1% DDC/SIRThep–/– mice had lower 
apoptosis (Supporting Fig. S11C,D) compared to 
0.1% DDC/WTs. Finally, ductular reaction and 
fibrosis were comparable in SIRThep–/– and WT 
mice 1 week after 0.1% DDC feeding (Supporting 
Fig. S11E,F). Western blotting analysis showed a 
decrease in FXR expression in both genotypes after 
DDC diet that was more pronounced in SIRThep–/– 
mice (Supporting Fig. S11G).
tHe BeNeFICIal eFFeCtS oF 
NorUDCa oN atteNUatINg 
CHoleStatIC lIVer 
INJUry aSSoCIate WItH 
tHe reDUCtIoN, BUt 
Not INHIBItIoN, oF SIrt1 
eXpreSSIoN
NorUDCA has proven efficacy in treating murine 
cholestasis in Mdr2–/– mice(25,26) and improving 
cholestasis in PSC patients.(5) We previously described 
that NorUDCA reduced SIRT1 expression in non-
cholestatic SIRToe mice, which associated with an 
improved response to injury and restored regenerative 
capacity of the liver.(16) These observations evidenced 
an alternative mechanism of action of this drug that 
may be relevant to cholestasis and lead us to investi-
gate the impact of NorUDCA on SIRT1 expression 
during cholestasis.
Our results show that NorUDCA significantly 
reduced SIRT1 expression in SIRToe mice during 
cholestasis after BDL, both at the gene transcript 
(Supporting Fig. S12A) and protein level (Fig. 
8A,B and Supporting Fig. S12B). Lower SIRT1 
expression correlated with higher FXR expression 
in NorUDCA/BDL/SIRToe mice compared to 
BDL/SIRToe (Fig. 8C and Supporting Fig. S12C). 
Reduced bile acid pool size was detected in livers 
from NorUDCA/SIRToe mice after BDL compared 
to BDL/SIRToe animals (Supporting Fig. S8D). 
These changes correlated with an obvious improve-
ment in liver parenchyma status in NorUDCA/
SIRToe mice after BDL as evidenced by hematoxy-
lin and eosin (H&E) staining (Fig. 8D), determina-
tion of serum liver injury markers (Supporting Fig. 
S12E), and reduced apoptotic cell death (Fig. 8E,F 
and Supporting. Fig. S12F). Finally, NorUDCA/
SIRToe mice showed a significant attenuation of 
ductular reaction (Fig. 8G) and fibrogenesis (Fig. 
8H and Supporting Fig. S12G) after BDL com-
pared to SIRToe animals.
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Notably, analysis of livers from Mdr2–/– mice 
confirmed that the described attenuation of the 
cholestatic phenotype exerted by NorUDCA treat-
ment(4) associates with the reduction of SIRT1 pro-
tein expression and nuclear localisation (Supporting 
Fig. S12H,I).
Taken together, our results support the importance 
of preserving the fine-tuning of SIRT1 expression to 
protect the liver from cholestasis-induced parenchy-
mal injury.
Discussion
In this study, we suggest that SIRT1 is up-regu-
lated in the liver during human and murine cholesta-
sis, and that it actively contributes to liver damage in 
this disease context.
Our results, showing that SIRT1 expression is 
increased in livers from both PBC and PSC choles-
tatic patients regardless of the disease etiology, sug-
gest that up-regulation of SIRT1 may be related 
to accumulation of bile acids in the liver occurring 
during obstructive cholestasis. Previous studies evi-
denced that UDCA and tauroursodeoxycholic acid 
induce SIRT1 expression,(27,28) whereas low doses 
(10-50 μM) of unconjugated species had no effect 
in modulating SIRT1.(28) Here, we show that pri-
mary, conjugated, and secondary bile acids (at a 
dose of 125 μM) significantly induce expression of 
SIRT1 in human liver THLE cells and in mouse 
primary hepatocytes, whereas no effect was observed 
at lower concentrations, supporting that the dosage 
of bile acids is crucial to regulate SIRT1. Different 
doses of bile acids have a differential impact on 
hepatocyte physiology; whereas low concentrations 
of bile acids (10-50 μM) act as signaling molecules, 
higher doses (from 50 to 200 μM) have a proapop-
totic action.(29-32) In accord, our results show that 
up-regulation of SIRT1 expression in response to 
bile acids (125 μM) correlates with apoptotic cell 
death in primary hepatocytes isolated from WT 
mice. Importantly, we found that inhibition of apop-
tosis had no impact on the up-regulation of SIRT1, 
supporting that SIRT1 is upstream of the apop-
totic response. Our additional studies confirmed 
the proapoptotic implication of SIRT1 up-regula-
tion in hepatocytes, given that apoptosis was further 
increased in SIRT1-overexpressing hepatocytes in 
response to bile acids, whereas it was significantly 
reduced in SIRT1-depleted hepatocytes compared 
to WT cells.
Further mechanistic in vitro studies pointed to 
the cross-talk regulation of SIRT1 and AMPK, 
which is essential to mediate bile-acid–induced cell 
death. Our results are in line with those in previous 
work showing that AMPK activation by metformin 
aggravated liver injury during xenobiotic-induced 
cholestasis, through mechanisms involving impaired 
FXR signaling,(33) and support the relevance of the 
SIRT1/AMPK axis in mediating bile-acid–induced 
cell death.
SIRT1 and AMPK are well-known metabolic 
regulators activated in response to metabolic chal-
lenges, including the decrease in cell energy lev-
els (e.g., during starvation/fasting).(23,24) During 
cholestasis, disruption of the flux of bile acids to 
the intestine contributes to deficient lipid absorp-
tion that overall impacts on the metabolic/energy 
status of the liver. Importantly, work from Moustafa 
et al.(34) showed that restoration of lipid metabo-
lism in Mdr2–/– mice after NorUDCA feeding 
or high-fat diet feeding protected the liver from 
cholestatic liver injury, pointing to the beneficial 
impact of increasing energy load during cholestasis. 
We propose that during cholestasis, the metabolic 
challenge involving lower nutrient/energy availabil-
ity, in addition to the increase bile acid load, con-
tribute to up-regulation of SIRT1 and subsequent 
liver damage. Supporting this, our in vitro studies 
FIg. 8. NorUDCA lowers SIRT1 expression leading to restored FXR signaling, improved liver parenchyma status, and reduced 
apoptosis, ductular reaction, and fibrogenesis after BDL. (A) IHC in liver sections using a SIRT1 Ab and (B) western blotting analysis 
showing reduction of SIRT1, but (C) sustained FXR protein expression in NorUDCA/SIRToe mice after BDL. (D) H&E staining of 
liver sections, (E) quantification of caspase-3 activity on liver protein lysates, and (F) TUNEL assay on liver sections from SIRToe and 
NorUDCA/SIRToe mice after BDL confirmed attenuation of parenchymal injury in the latter. (G) CK19 IHC as well as (H) Sirius 
Red staining and aSMA IHC on liver sections, all followed by morphometric analyses, confirmed the beneficial impact of NorUDCA 
in BDL/SIRToe mice. All images at original magnification 10× or 20× (SIRT1). Values are mean ± SEM; n ≥ 5 animals/time point; 
*P < 0.05; **P < 0.01 (SIRT vs. NorUDCA/SIRT). Abbreviations: Ab, antibody; NorUDCA, nor-ursodeoxycholic acid; NorUDCA/
SIRT1oe overexpressing mice that have been treated with NorUDCA.
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show that serum-supplementation to culture media 
associated with reduced SIRT1 and AMPK activa-
tion and lower apoptosis in response to bile acids 
in comparison to starved hepatocytes. Although fur-
ther work investigating in vivo activation of AMPK 
during cholestasis is required, our in vitro studies 
point to a role for AMPK in regulating SIRT1 and 
detrimental activity during cholestasis. Collectively, 
our results and those previously published(33,34) 
highlight the metabolic characteristic of cholestatic 
disease.
To gain further insight into the biological relevance 
of SIRT1 regulation during cholestasis, we performed 
BDL and fed SIRT1-overexpressing mice with a 0.1% 
DDC diet that showed exacerbated parenchymal liver 
injury when compared to WT animals. Additional in 
vivo studies showed that the reduction, but not com-
plete inhibition, of SIRT1 expression in liver had a 
therapeutic potential to improve liver parenchyma sta-
tus during cholestasis. Thus, attenuation of liver injury 
in BDL/SIRToe mice after NorUDCA treatment cor-
related with a reduction of SIRT1 expression, whereas 
hepatocyte-targeted SIRT1 depletion in SIRThep–/– 
mice lead to a transient improvement in liver function 
that was offset at later stages after BDL. Regulation 
of FXR by SIRT1 may represent a key mechanism 
mediating these outcomes.
FXR is the main regulator of bile acid homeo-
stasis. During cholestasis, FXR signaling mediates 
an adaptive response aiming to reduce bile acid pool 
size by inhibiting bile acid synthesis and modulat-
ing their transport.(35) FXR currently represents a 
promising target for therapeutic approaches to treat 
human cholestatic disease.(7-9) Regulation of FXR 
involves a dynamic deacetylation process coordinated 
by SIRT1(14) and is needed for FXR-DNA bind-
ing and target gene transcription, whereas the same 
process regulates FXR proteasomal degradation.(14) 
In accord, we previously described that FXR was 
reduced in SIRT1-overexpressing mice.(16) Here, we 
provide further evidence of the relevance of SIRT1/
FXR signaling during cholestasis. Thus, whereas 
SIRT1 overexpression reduced FXR signaling, attenu-
ation of SIRT1 after NorUDCA treatment efficiently 
restored FXR expression after BDL. Interestingly, we 
also observed reduced FXR signaling in SIRT1hep–/– 
mice, as described in previous studies(36) that associ-
ated with a transient reduction of liver injury after 
BDL, suggesting that depletion of SIRT1/FXR in 
hepatocytes may protect the liver at early stages of 
obstructive cholestasis. This is supported by previous 
studies,(11,35,37) including work from Wagner et al., 
showing that whole-body FXR-deficient mice had 
lower intrabiliary pressure after BDL overall relating 
to less bile infarcts and attenuated liver damage after 
BDL.(11) Similarly, we found reduced ductular reac-
tion at early stages of cholestasis in both SIRToe and 
SIRT1hep–/– mice, though differences were not statisti-
cally significant in the latter and became comparable 
to WT mice at later stages after BDL.
As cholestatic disease progresses, cholangiocytes 
lose their proliferative capacity in advanced disease, 
contributing to bile duct loss (ductopenia).(3) Our 
results point to the contribution of SIRT1 to this 
process and support the previously described ability of 
mild SIRT1 overexpression to inhibit the proliferative 
effect of growth factors like progranulin in vitro.(38)
Ultimately, the apparent differences in severity 
of the damaging phenotype observed in SIRT1-
overexpressing mice when compared to SIRT1hep–/– 
mice, despite the similarly attenuation of FXR 
signaling, support that apoptotic cell death associated 
with increased SIRT1 expression play a key role in 
contributing to liver injury during cholestasis.
Several studies using NorUDCA treatment in 
murine models of cholestasis,(4,25,39,40) and a recently 
conducted phase II human clinical trial,(5) support 
the benefits of this drug as a treatment option for 
cholestatic patients.(5,41) In our present work, we show 
that NorUDCA modulates SIRT1 expression in two 
alternative models of cholestasis: in SIRToe mice after 
BDL and in Mdr2–/– mice. Importantly, our results 
show that only the modulation of SIRT1 exerted by 
NorUDCA, but not the complete depletion (as in our 
hepatocyte-KO mice), preserved FXR signaling and 
overall liver function after BDL, emphasizing the rel-
evance of maintaining fine-tuned SIRT1 expression 
to protect the liver during cholestasis. In our studies, 
we cannot discern whether SIRT1 regulation is a mere 
consequence of the reduced bile acid pool size in the 
liver or is a direct effect of NorUDCA on SIRT1. As 
discussed, other factors, like restoration of liver energy 
metabolism upon NorUDCA treatment,(34) may also 
impact on SIRT1 regulation.
Our observations are relevant to recent studies that 
propose the use of SIRT1 activators to counteract 
murine cholestasis after CA feeding in mice.(28) It is 
worth noting that after bile acid feeding, SIRT1 was 
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differently regulated than during human and murine 
obstructive cholestasis, where SIRT1 expression is 
significantly elevated. Although it is out of the scope 
of our current study to resolve differential SIRT1 
expression during CA feeding and after BDL, previ-
ous studies have revealed marked differences between 
these two experimental models.(11,42) For example, 
CA feeding regulates intestinal pathways that feed-
back to control bile acid metabolism in the liver in 
a different way to that during obstructive cholesta-
sis, which involves the absence of bile acids in the 
intestine. Hence, CA feeding commonly results in 
inhibition of Cyp7A1,(43) likely mediated by intesti-
nal-derived feedback mechanisms involving activation 
of ileal FXR,(44) whereas obstructive cholestasis after 
BDL results in initial reduction (Figs. 4 and 5), but 
later recovery of Cyp7A1 expression and bile acid syn-
thesis.(44) Furthermore, treatment with SIRT1 activa-
tors in CA-fed mice had no impact on SIRT1 gene 
expression and protein expression was only modestly 
induced after treatment, rendering a SIRT1 expres-
sion comparable to that found at basal homeostatic 
conditions.(28) These observations ultimately support 
our conclusions underscoring the importance of main-
taining a fine-tuned SIRT1 expression in the liver to 
counteract cholestasis.
In summary, our work raises awareness that expres-
sion levels of SIRT1 should be considered when 
designing therapeutic strategies to treat cholestasis, 
which should aim to the attenuation, though not 
complete inhibition, of SIRT1. Overall, our results 
underline the critical relevance of maintaining the 
fine-tuning of SIRT1 expression to preserve liver 
health.
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